Stifel holds Vertex stock with $194 target post-Q1 results

Tuesday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a $112.6 billion biotechnology company that has delivered an impressive 24% return year-to-date, received a reiterated Hold rating from Stifel analysts, with a maintained price target of $194.00. The analysts provided insights following the company’s first-quarter earnings report. They noted that Vertex’s revenue slightly missed the consensus estimates but highlighted that the lower end of the company’s revenue guidance has been raised. According to InvestingPro data, the company maintains strong revenue growth of 11.7% over the last twelve months.

In their assessment, Stifel analysts pointed out that the first-quarter performance did not significantly alter the investment thesis for Vertex. The attention remains on the launch of Journavx, Vertex’s new medication. Early prescription data for Journavx appear promising, although it is still the initial phase of the launch. The primary goal for the first year is to establish a reliable supply chain and ensure access to the medication. With an "GOOD" overall Financial Health score from InvestingPro and a strong current ratio of 2.69, the company appears well-positioned to support this launch.

On the other hand, another Vertex drug, Alyftrek, did not meet consensus expectations in terms of sales. This was not unexpected, according to Stifel analysts, as their checks with key opinion leaders suggested that many patients currently treated with Trikafta, who are generally stable, may not see additional benefits from switching to Alyftrek.

Stifel analysts further mentioned that the major variable influencing Vertex’s stock performance through 2025 and 2026 would likely be the success or failure of the Phase 3 program for suzetrigine, a treatment for diabetic peripheral neuropathy (DPN). They described this as a binary outcome, which could significantly impact the company’s valuation.

In addition to these developments, Vertex is noted to be making strides in its extensive pipeline, which includes treatments for pain, autoimmune diseases, type 1 diabetes, and renal diseases. This progress is occurring in the background while the company navigates the challenges and opportunities of its current product offerings. Based on InvestingPro analysis, the company’s stock currently trades near its Fair Value, with analysts maintaining mixed views as reflected in their consensus recommendation of 2.03. For deeper insights into Vertex’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

In other recent news, Vertex Pharmaceuticals reported its first-quarter 2025 earnings, revealing a shortfall in both earnings per share (EPS) and revenue. The company’s revenue reached $2.77 billion, falling short of the expected $2.86 billion, while EPS came in at $4.06, below the anticipated $4.26. Despite these misses, Vertex raised its 2025 revenue guidance to between $11.85 billion and $12 billion. Analysts at Scotiabank (TSX:BNS) and Leerink Partners adjusted their outlooks on Vertex, with Scotiabank maintaining a Sector Perform rating but lowering the price target from $450 to $442, and Leerink downgrading the stock from "Outperform" to "Market Perform" with a reduced price target from $550 to $503.

The underperformance was partly due to lower-than-expected sales of Vertex’s cystic fibrosis drugs, Alyftrek and Trikafta, with the latter impacted by intellectual property issues in Russia. However, the company noted positive developments in the initial prescription volumes for its new CF treatment, Journavx, which has seen 20,000 prescriptions filled. Leerink Partners highlighted challenges in Journavx’s market access and tempered its sales forecasts for the drug. Despite these hurdles, Vertex continues to expand its pipeline, with new product launches like Gernavix, and remains focused on commercialization and regulatory progress for its diverse portfolio.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.